Overview
Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).
Indication
用于敏感菌所致的呼吸道感染、泌尿道感染，妇科、外科、耳鼻喉科和皮肤科等感染的治疗。
Associated Conditions
No associated conditions information available.
Research Report
Pazufloxacin Report
Name: Pazufloxacin Name (English): Pazufloxacin DrugBank ID: DB11774 Type: Small Molecule CAS Number: 127045-41-4
Molecular Formula: $\mathrm{C}{16} \mathrm{H}{15} \mathrm{FN}{2} \mathrm{O}{4}$ Molecular Weight: 318.304 g/mol
Synonyms:
- T-3761
- (3S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
- (S)-10-(1-Aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
- 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-
- Pazufloxacine
- Pazufloxacino
Pharmacology: Pazufloxacin is a fluoroquinolone antibiotic. It inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. It demonstrates broad-spectrum antibacterial activity against Gram-negative and some Gram-positive bacteria, including strains resistant to cephalosporins, carbapenems, and aminoglycosides.
Indications: Pazufloxacin is marketed in some regions for the treatment of various bacterial infections, including respiratory and urinary tract infections. Clinical trials have also investigated its use in bacterial conjunctivitis.
Pharmacokinetics: Pazufloxacin exhibits good oral bioavailability and tissue penetration. It is mainly excreted in urine and has a short half-life (2-2.5 hours).
Drug Interactions: Pazufloxacin has the potential for numerous drug interactions. Examples include increased risk of QTc prolongation with certain medications, altered efficacy of antidiabetic agents, increased neuroexcitatory activities with NSAIDs, and decreased absorption with antacids containing aluminum or magnesium. It can also affect the metabolism of various drugs.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2020/05/12 | Phase 3 | Completed | Eurofarma Laboratorios S.A. | ||
2018/10/04 | Phase 3 | Terminated | |||
2018/09/18 | Phase 1 | UNKNOWN | Lee's Pharmaceutical Limited | ||
2016/12/02 | Phase 2 | Completed | |||
2015/10/30 | Phase 1 | UNKNOWN | Lee's Pharmaceutical Limited | ||
2008/07/21 | Phase 4 | Completed | |||
2007/05/10 | Phase 3 | Completed | Diamond Headache Clinic |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.